Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$24.16 +2.7%	$28.68	$22.74 ▼ $53.96	$1.15B	0.79	456,879 shs	482,792 shs
DYN Dyne Therapeutics	$7.04 +0.9%	$11.86	$6.36 ▼ $47.45	$796.37M	1.21	1.47 million shs	1.35 million shs
INDV Indivior	$9.11 +1.9%	$9.61	$7.33 ▼ $20.10	$1.26B	0.93	927,836 shs	695,449 shs
MREO Mereo BioPharma Group	$1.95 +6.6%	$2.49	$1.58 ▼ $5.02	$302.54M	0.71	1.05 million shs	1.15 million shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	+2.72%	-9.21%	-8.07%	-33.55%	-39.68%
DYN Dyne Therapeutics	+0.86%	-14.98%	-43.04%	-55.64%	-73.76%
INDV Indivior	+1.90%	-0.44%	-6.66%	-23.12%	-55.28%
MREO Mereo BioPharma Group	+6.56%	-2.01%	-23.23%	-45.07%	-33.67%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMPH Amphastar Pharmaceuticals	4.2685 of 5 stars	3.0	3.0	3.7	2.8	4.2	1.3
DYN Dyne Therapeutics	3.2295 of 5 stars	4.5	1.0	0.0	3.4	4.2	0.0
INDV Indivior	3.3017 of 5 stars	3.6	3.0	0.0	3.2	1.7	1.9
MREO Mereo BioPharma Group	2.6152 of 5 stars	3.6	4.0	0.0	3.2	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMPH Amphastar Pharmaceuticals	2.00	Hold	$43.50	80.05% Upside
DYN Dyne Therapeutics	3.07	Buy	$47.46	574.17% Upside
INDV Indivior	3.25	Buy	$15.00	64.65% Upside
MREO Mereo BioPharma Group	3.25	Buy	$7.71	295.60% Upside

Current Analyst Ratings Breakdown

Latest MREO, AMPH, INDV, and DYN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/10/2025	AMPH Amphastar Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
4/9/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
3/27/2025	MREO Mereo BioPharma Group	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$7.00
3/26/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
3/21/2025	AMPH Amphastar Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$36.00 ➝ $32.00
3/21/2025	DYN Dyne Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$18.00 ➝ $17.00
3/18/2025	MREO Mereo BioPharma Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$7.00 ➝ $7.00
3/17/2025	DYN Dyne Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00 ➝ $46.00
3/17/2025	DYN Dyne Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
3/12/2025	DYN Dyne Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$50.00
3/7/2025	DYN Dyne Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$50.00

(Data available from 4/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMPH Amphastar Pharmaceuticals	$731.97M	1.57	$3.37 per share	7.17	$13.35 per share	1.81
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$1.49 per share	N/A
INDV Indivior	$1.19B	1.06	$1.84 per share	4.94	N/A	∞
MREO Mereo BioPharma Group	$1M	302.53	N/A	N/A	$0.36 per share	5.42

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMPH Amphastar Pharmaceuticals	$137.54M	$3.06	8.05	7.34	2.19	21.80%	26.44%	11.89%	5/6/2025 (Estimated)
DYN Dyne Therapeutics	-$235.94M	-$3.35	N/A	N/A	N/A	N/A	-57.46%	-51.62%	5/1/2025 (Estimated)
INDV Indivior	$2M	-$0.35	N/A	5.33	N/A	-3.96%	-241.73%	15.09%	4/24/2025 (Estimated)
MREO Mereo BioPharma Group	-$29.47M	-$0.06	N/A	N/A	N/A	N/A	N/A	N/A	5/21/2025 (Estimated)

Latest MREO, AMPH, INDV, and DYN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2025	Q1 2025	DYN Dyne Therapeutics	-$0.88	N/A	N/A	N/A	N/A	N/A
4/24/2025	Q1 2025	INDV Indivior	$0.22	N/A	N/A	N/A	$240.13 million	N/A
3/26/2025	Q4 2024	MREO Mereo BioPharma Group	$0.02	-$0.01	-$0.03	-$0.01	$72.50 million	N/A
3/4/2025	Q4 2024	DYN Dyne Therapeutics	-$0.92	-$0.88	+$0.04	-$0.88	N/A	N/A
2/20/2025	Q4 2024	INDV Indivior	$0.32	$0.32	N/A	$0.07	$262.35 million	$298.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
INDV Indivior	N/A	N/A	N/A	N/A	N/A
MREO Mereo BioPharma Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMPH Amphastar Pharmaceuticals	0.82	3.43	2.61
DYN Dyne Therapeutics	N/A	17.02	17.02
INDV Indivior	N/A	0.83	0.65
MREO Mereo BioPharma Group	N/A	6.10	6.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMPH Amphastar Pharmaceuticals	65.09%
DYN Dyne Therapeutics	96.68%
INDV Indivior	60.33%
MREO Mereo BioPharma Group	62.83%

Insider Ownership

Company	Insider Ownership
AMPH Amphastar Pharmaceuticals	27.10%
DYN Dyne Therapeutics	20.77%
INDV Indivior	N/A
MREO Mereo BioPharma Group	4.13%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMPH Amphastar Pharmaceuticals	1,620	47.65 million	35.05 million	Optionable
DYN Dyne Therapeutics	100	113.12 million	80.63 million	Optionable
INDV Indivior	1,164	137.88 million	N/A	Not Optionable
MREO Mereo BioPharma Group	40	155.15 million	148.74 million	Optionable

MREO, AMPH, INDV, and DYN Headlines

Recent News About These Companies

Mereo BioPharma Group plc (NASDAQ:MREO) Given Average Recommendation of "Buy" by Brokerages

April 12 at 1:34 AM | marketbeat.com

Mereo BioPharma Group (NASDAQ:MREO) Given "Buy" Rating at Needham & Company LLC

April 11 at 8:48 AM | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Avidity Biosciences (RNA), Mereo Biopharma Group Plc (MREO) and Doximity (DOCS)

April 9 at 3:59 PM | markets.businessinsider.com

Mereo BioPharma’s SWOT analysis: rare disease stock poised for breakthrough

April 2, 2025 | uk.investing.com

Cantor Fitzgerald Forecasts MREO FY2025 Earnings

March 31, 2025 | marketbeat.com

Research Analysts Offer Predictions for MREO Q1 Earnings

March 31, 2025 | marketbeat.com

JPMorgan Chase & Co. Begins Coverage on Mereo BioPharma Group (NASDAQ:MREO)

March 28, 2025 | marketbeat.com

Mereo BioPharma initiated with an Overweight at JPMorgan

March 27, 2025 | markets.businessinsider.com

Cantor Fitzgerald Remains a Buy on Mereo Biopharma Group Plc (MREO)

March 27, 2025 | markets.businessinsider.com

JP Morgan Initiates Coverage of Mereo BioPharma Group plc - Depositary Receipt () (MREO) with Overweight Recommendation

March 27, 2025 | msn.com

Mereo BioPharma Group's (MREO) Buy Rating Reaffirmed at Needham & Company LLC

March 27, 2025 | marketbeat.com

Mereo BioPharma Group (NASDAQ:MREO) Releases Earnings Results, Misses Estimates By $0.03 EPS

March 27, 2025 | marketbeat.com

Mereo BioPharma sees cash runway into 2027

March 27, 2025 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Allurion Technologies (ALUR), Savara (SVRA)

March 27, 2025 | markets.businessinsider.com

Mereo BioPharma Group plc: Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights

March 26, 2025 | finanznachrichten.de

Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights

March 26, 2025 | globenewswire.com

Mereo BioPharma’s SWOT analysis: setrusumab, alvelestat drive rare disease stock potential

March 21, 2025 | uk.investing.com

MEREO BIOPHARMA (MREO) Upgraded to Buy: What Does It Mean for the Stock?

March 20, 2025 | zacks.com

Mereo BioPharma Group (NASDAQ:MREO) Receives Overweight Rating from Cantor Fitzgerald

March 19, 2025 | marketbeat.com

Tejara Capital Ltd Reduces Stock Position in Mereo BioPharma Group plc (NASDAQ:MREO)

March 19, 2025 | marketbeat.com

Mereo BioPharma Group (MREO) to Release Quarterly Earnings on Wednesday

March 19, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MREO, AMPH, INDV, and DYN Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

$24.16 +0.64 (+2.72%)

Closing price 04/11/2025 04:00 PM Eastern

Extended Trading

$24.12 -0.04 (-0.17%)

As of 04/11/2025 06:07 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Dyne Therapeutics NASDAQ:DYN

$7.04 +0.06 (+0.86%)

Closing price 04/11/2025 04:00 PM Eastern

Extended Trading

$7.04 0.00 (-0.07%)

As of 04/11/2025 04:13 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Indivior NASDAQ:INDV

$9.11 +0.17 (+1.90%)

Closing price 04/11/2025 04:00 PM Eastern

Extended Trading

$9.10 -0.01 (-0.11%)

As of 04/11/2025 04:05 PM Eastern

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Mereo BioPharma Group NASDAQ:MREO

$1.95 +0.12 (+6.56%)

Closing price 04/11/2025 04:00 PM Eastern

Extended Trading

$1.92 -0.02 (-1.28%)

As of 04/11/2025 05:38 PM Eastern

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time